eCite Digital Repository

Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy

Citation

Jellis, CL and Sacre, JW and Wright, J and Jenkins, C and Haluska, B and Jeffriess, L and Martin, J and Marwick, TH, Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy, European Heart Journal Cardiovascular Imaging, 15, (7) pp. 776-786. ISSN 2047-2404 (2014) [Refereed Article]

Copyright Statement

Copyright 2014 the authors

DOI: doi:10.1093/ehjci/jeu013

Abstract

BACKGROUND: Subclinical diabetic cardiomyopathy (DCM) is frequent in asymptomatic subjects with type 2 diabetes (T2DM). We sought the response of functional and fibrosis markers to therapy in a trial of aldosterone antagonism for treatment of DCM. METHODS: Biochemical, anthropometric, and echocardiographic data were measured in 225 subjects with T2DM. Myocardial function was evaluated with standard echocardiography and myocardial deformation; ischaemia was excluded by exercise echocardiography. Calibrated integrated backscatter and post-contrast T1 mapping from cardiac magnetic resonance imaging were used to assess myocardial structure. Amino-terminal propeptides of pro-collagen type I (PINP) and III (PIIINP), the carboxy-terminal propeptide of pro-collagen type I (PICP) and transforming growth factor beta-1 were measured from peripheral blood or urine to assess myocardial collagen turnover. RESULTS: Diastolic dysfunction was identified in 81 individuals, of whom 49 (25 male, age 60 10 years) were randomized to spironolactone 25 mg/day or placebo therapy for 6 months. Groups were well-matched at baseline. Spironolactone therapy was associated with improvements in diastolic filling profile (Δpeak E wave velocity -4 15 vs. 9 10 ms, P = 0.001; ΔE/A ratio -0.1 0.3 vs. 0.2 0.2, P < 0.001) and cIB values (-21.2 4.5 dB vs. -18.0 5.2 dB, P = 0.026; ΔcIB -5.1 6.8 vs. -1.3 5.2, P = 0.030). ΔcIB was independently associated with spironolactone therapy (β = 0.320, P = 0.026) but not Δblood pressure. With intervention, pro-collagen biomarkers (ΔPINP P = 0.92, ΔPICP P = 0.25, ΔPIIINP P = 0.52, and ΔTGF-β1 P = 0.71) and T1 values (P = 0.54) remained similar between groups. CONCLUSIONS: Spironolactone-induced changes in myocardial structure and diastolic properties in DCM are small, and are unassociated with changes in collagen biomarkers or T1 values.

Item Details

Item Type:Refereed Article
Keywords:Pro-collagen biomarkers, diabetic cardiomyopathy, myocardial fibrosis, diastolic dysfunction, backscatter, T1 mapping, spironolactone
Research Division:Medical and Health Sciences
Research Group:Cardiorespiratory Medicine and Haematology
Research Field:Cardiology (incl. Cardiovascular Diseases)
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Cardiovascular System and Diseases
Author:Marwick, TH (Professor Tom Marwick)
ID Code:93351
Year Published:2014
Web of Science® Times Cited:5
Deposited By:Menzies Institute for Medical Research
Deposited On:2014-07-29
Last Modified:2017-10-31
Downloads:0

Repository Staff Only: item control page